Oragon 150 mg (Tablet)
Unit Price: ৳ 170.00 (2 x 6: ৳ 2,040.00)
Strip Price: ৳ 1,020.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Elagolix sodium |
| Company | Renata limited |
Indications
- Management of moderate to severe pain associated with endometriosis
Pharmacology
- GnRH receptor antagonist
- Inhibits endogenous GnRH signaling by binding competitively to GnRH receptors
- Results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
Dosage & Administration
- Pregnancy exclusion before starting treatment
- Start within 7 days from the onset of menses
- Different treatment options based on hepatic impairment and dyspareunia
- Contraindicated for use in children and adolescents below 18 years
Interactions
- May potentiate P-gp substrates (e.g. digoxin)
- May antagonize oral midazolam, rosuvastatin
- Reduced efficacy with estrogen-containing contraceptives
- No known food interactions
Contraindications
- Contraindicated in pregnant women
- Contraindicated with known osteoporosis
- Contraindicated for severe hepatic impairment
- Contraindicated with concomitant use of strong OATP1B1 inhibitors
Side Effects
- Common side effects include hot flushes, night sweats, headache, nausea, amenorrhea, arthralgia, mood changes, and bone loss
- Rare side effects include insomnia, anxiety, and elevated hepatic transaminase
Pregnancy & Lactation
- Limited human data for use in pregnant women
- Increased risk of early pregnancy loss
- Contraindicated in pregnant women
- Discontinue if pregnancy occurs during treatment
- No information on effects on breastfeeding or milk production
Precautions & Warnings
- Dose and duration-dependent decreases in bone mineral density (BMD)
- Reduced ability to recognize pregnancy
- Suicidal ideation and mood disorders
- Dose-dependent elevations in serum alanine aminotransferase (ALT)
- Potential for reduced efficacy with estrogen-containing contraceptives
Use in Special Populations
- No dose adjustment required in women with any degree of renal impairment or end-stage renal disease
- No dosage adjustment required in women with mild hepatic impairment
- Safety and effectiveness in patients less than 18 years not established
Overdose Effects
- Patients should be monitored for signs or symptoms of adverse reactions
- Initiate appropriate symptomatic treatment if needed
Therapeutic Class
- Gonadotropin-releasing hormone (GnRH) antagonist
Storage Conditions
- Store in a cool & dry place
- Protect from light & moisture
- Keep all medicines out of reach of children